The global retinal vein occlusion treatment market is expected to be valued at US$ 2.3 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 5.9% to reach US$ 4.7 billion during forecast 2023 to 2033. Retinal vein occlusion is one of the most prevalent retinal vascular illnesses in older individuals, primarily affecting people over the age of 65. Age is a major potential risk for retinal vein occlusion. As the geriatric population rises, it is expected that the incidence of retinal vein occlusion will emerge as well.
Players in the retinal vein occlusion treatment market are expanding their capacity for producing corticosteroid drugs, which can aid in combating the inflammatory elements that cause edema. Medical practitioners, on the other side, are increasingly becoming proficient in focal laser therapy. This treatment applies lasers to places of swelling, allowing edema to reduce. Many retinal vein occlusion market stakeholders are investing more in pan-retinal photocoagulation therapy advancement and research. In instances of BRVO with neovascularization or macular edema, anti-vascular endothelial growth factor (anti-VEGF) medicines including Lucentis, Avastin, and Eylea are often used.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry growth. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry expansion. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Due to various effective healthcare facilities, an increment in the pervasiveness of eye disorders, sophisticated technology, and a boost in the ageing population, North America held a significant portion of the global retinal vein occlusion market in 2022. From 2023 to 2033, the Asia Pacific retinal vein occlusion market is predicted to grow at a 6.5% CAGR. The increasing prevalence of eye conditions in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising healthcare spending, are predicted to propel market expansion in Asia Pacific from 2023 to 2033.
The retinal vein occlusion industry in the Middle East and Africa is expected to grow due to the presence of a sophisticated medical system. Due to limited access to medical infrastructure and the sluggish advancement of the healthcare industry, the MEA market is expected to grow gradually. Nations such as Kuwait and Qatar, on the other hand, are focusing more on the medical industry and burgeoning healthcare facilities, which will strengthen the region's industry. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 2.3 billion |
| Anticipated Forecast Value (2033) | US$ 4.7 billion |
| Projected Growth Rate (2023 to 2033) | 5.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The decline in industry growth was mainly due to the COVID-19 pandemic, which has resulted in strict containment approaches such as social distancing, remote employment, and the closure of industries and other economic operations, deriving in organizational hardships. The entire distribution chain has been impacted, which has had a negative impact on the retinal vein occlusion treatment market in the past.
However, now, that the industries are getting back to their normal functioning, the global demand for retinal vein occlusion treatment is projected to increase at a CAGR of 5.9% during the forecast period between 2023 and 2033, reaching a total of US$ 4.7 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5%.
The rising prevalence of Atherosclerosis and diabetes drives market expansion
The increased incidence of atherosclerosis and diabetes is predicted to drive market expansion. Because atherosclerosis is primarily asymptomatic, determining the prevalence rate is hard. Atherosclerosis is widely regarded as the leading cause of cardiovascular disease. As a result, the increasing incidence of cardiovascular diseases is attributed to the retinal vein occlusion treatment industry growth.
Based on the International Diabetes Federation (IDF), approximately 537 million adults suffered from diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. In addition, approximately 610,000 deaths occur from heart disease in the United States annually. That equates to one out of every four deaths.
Coronary heart disease is the main cause of mortality in the Western world, claiming the lives of over 370,000 people each year as per the report published in the National Library of Medicine. As a result, expanding the pervasiveness of secondary conditions may boost RVO incidence and industry growth.
Availability of Multiple Medical Therapies to fuel Market Growth
Presently, there is no therapeutic option to reverse retinal vein occlusions. There are, nevertheless, numerous medical therapies obtainable to control RVO complications. Anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy are a few of the therapy methods. Anti-VEGF injection therapy is regarded as the first curative therapy for patient populations with BRVO or CRVO who have macular edema.
Anti-VEGF therapy has resulted in significant advances in macular edema patients. For those who suffer from macular edema, corticosteroids, such as dexamethasone implant (OZURDEX) are termed second-line therapy. Therefore, the prevalence of various therapies is predicted to drive market growth.
Principal Consultant
High Costs to Hinder Market Growth
The demand is anticipated to be hindered by the present unmet medical needs in the retinal vein occlusion industry for care that restores vision while remaining inexpensive.
There is no doubt that the emergence of biosimilars into the Retinal vein occlusion market will reduce expansion in the forthcoming years. During the projected timeframe, high treatment-related expenses and linked side effects of these treatments are anticipated to stymie demand.
Extensive Development of Ophthalmology Infrastructure of the Pharmaceutical Industry to drive growth
North America would retain a huge proportion throughout the forecast timeframe. The USFDA's authorization of advanced anti-VEGF medicines in the US, the pharma industry's massive ophthalmology infrastructure, and recurring medical studies for retinal ailments all contribute to the industry's growth.
Moreover, according to the report published in Vitreous Retina Macula Consultants of New York, New York ophthalmologists and retinal ocular specialists release more research on the therapeutic interventions for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in the leading peer-reviewed publications than any other personal or scholarly group in the USA. Also, they created numerous existing theories in retinal disease and several of the best therapeutic approaches recognized worldwide. As a result, this factor is expected to propel the market.
Regulatory Drug Approvals drive Regional Market Growth
Europe is expected to have the second-largest sales volume during the forecast years owing to the high prevalence of regulatory drug approvals. The Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom approved marketing approval for Ximluci, a ranibizumab biosimilar created in collaboration between STADA Arzneimittel and Xbrane Biopharma, in January 2023. Since the approval of Teva Pharmaceuticals' Ongavia in May 2022, this is the 2nd ranibizumab biosimilar for the UK industry. Ranibizumab is a vascular endothelial growth variable obstacle used to cure retinal diseases such as retinal vein occlusion.
According to a 2018 Pubmed report, the random-effects gathered incidence of RVO in Europeans over the age of 55 was 0.7%. The overall population of affected people in the EU is expected to increase by nearly 20%, from 900,000 in 2018 to 1.1 million in 2050. The rise of a huge aged population, along with high healthcare investment, are the other attributes driving the retinal vein occlusion market expansion in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Branch Retinal Vein Occlusion segment held the highest market share globally
In 2022, the branch retinal vein occlusion segment held the largest global retinal vein occlusion therapeutics revenue growth. As a result of the growing incidence of elevated blood pressure, cardiovascular disease, and glaucoma, this segment is predicted to dominate the market. This segment is anticipated to expand at a CAGR of 6% over the forecast timeframe.
Hospitals are Estimated to Hold the Largest Share
In 2022, the hospital segment led the market, accounting for 46% of total revenue. Hospitals are usually regarded as primary healthcare systems, and the patient population's priority for hospitals for the assessment and treatment of chronic disorders is also stirring up segment growth.
Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals, Novartis AG. Some of the latest developments by the manufacturers are below
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 2.3 billion |
| Market Value in 2033 | US$ 4.7 billion |
| Growth Rate | CAGR of 5.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The market value for 2023 is US$ 2.3 billion.
Through 2033, market sales are likely to rise at a 5.9% CAGR.
The market rose at a 5% CAGR from 2018 to 2022.
Growing preference for biosimilars could hinder market growth.
Branch retinal vein occlusion is likely to be the key type segment through 2033.
1. Executive Summary | Retinal Vein Occlusion Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Ranibizumab
5.3.2. Dexamethasone
5.3.3. Aflibercept
5.3.4. Bevacizumab
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis , 2023 to 2033
7.3.1. Optical Coherence Tomography
7.3.2. Fundoscopic Examination
7.3.3. Fluorescein Angiography
7.4. Y-o-Y Growth Trend Analysis By Diagnosis , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Diagnosis , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
8.3.1. Hospitals
8.3.2. Research and Academics
8.3.3. Specialty Clinics
8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The United States
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Type
10.2.4. By Diagnosis
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Type
10.3.4. By Diagnosis
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Type
11.2.4. By Diagnosis
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Type
11.3.4. By Diagnosis
11.3.5. By End User
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Type
12.2.4. By Diagnosis
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Type
12.3.4. By Diagnosis
12.3.5. By End User
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Class
13.2.3. By Type
13.2.4. By Diagnosis
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Type
13.3.4. By Diagnosis
13.3.5. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Type
14.2.4. By Diagnosis
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Type
14.3.4. By Diagnosis
14.3.5. By End User
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Class
15.2.3. By Type
15.2.4. By Diagnosis
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Type
15.3.4. By Diagnosis
15.3.5. By End User
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Type
16.2.4. By Diagnosis
16.2.5. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Type
16.3.4. By Diagnosis
16.3.5. By End User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Type
17.1.2.3. By Diagnosis
17.1.2.4. By End User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Type
17.2.2.3. By Diagnosis
17.2.2.4. By End User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Type
17.3.2.3. By Diagnosis
17.3.2.4. By End User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Type
17.4.2.3. By Diagnosis
17.4.2.4. By End User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Type
17.5.2.3. By Diagnosis
17.5.2.4. By End User
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Type
17.6.2.3. By Diagnosis
17.6.2.4. By End User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Type
17.7.2.3. By Diagnosis
17.7.2.4. By End User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Type
17.8.2.3. By Diagnosis
17.8.2.4. By End User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Type
17.9.2.3. By Diagnosis
17.9.2.4. By End User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Type
17.10.2.3. By Diagnosis
17.10.2.4. By End User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Type
17.11.2.3. By Diagnosis
17.11.2.4. By End User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Type
17.12.2.3. By Diagnosis
17.12.2.4. By End User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Type
17.13.2.3. By Diagnosis
17.13.2.4. By End User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Type
17.14.2.3. By Diagnosis
17.14.2.4. By End User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Type
17.15.2.3. By Diagnosis
17.15.2.4. By End User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Type
17.16.2.3. By Diagnosis
17.16.2.4. By End User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Type
17.17.2.3. By Diagnosis
17.17.2.4. By End User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Type
17.18.2.3. By Diagnosis
17.18.2.4. By End User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Type
17.19.2.3. By Diagnosis
17.19.2.4. By End User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Type
17.20.2.3. By Diagnosis
17.20.2.4. By End User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Class
17.21.2.2. By Type
17.21.2.3. By Diagnosis
17.21.2.4. By End User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Type
18.3.4. By Diagnosis
18.3.5. By End User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. AbbVie
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. F. Hoffmann- La Roche AG
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Regeneron Pharmaceuticals
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Taiwan Liposome Company
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Aerie Pharmaceuticals
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Graybug Vision
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Outlook Therapeutics
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Kodiak Sciences Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Chugai Pharmaceuticals Co. Ltd.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Novartis AG
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Retinal Vein Occlusion Treatment Market
